There's a flood of reports about college students
apparently using AI to cheat their way through college, and debating whether or not that's the actual problem. Now, NBC4 in Columbus points out Ohio State's new AI Fluency plan that targets the class of 2029 (with some level of assumptions that our current view of generative AI will still be relevant by then), focusing on a few steps:
All undergraduates will be introduced to generative AI basics in the required General Education Launch Seminar.
GenAI workshops will be integrated into the First Year Success Series.
The new 'Unlocking Generative AI' course will be offered and open to all majors.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Former OpenAI Board Member Questions Zuckerberg AI Hiring Spree
(Bloomberg) -- Meta Platforms Inc.'s lavish multimillion-dollar budget for recruiting top AI talent may not guarantee success, said Helen Toner, former OpenAI board member and director of strategy at Georgetown's Center for Security and Emerging Technology. NYC Commutes Resume After Midtown Bus Terminal Crash Chaos Struggling Downtowns Are Looking to Lure New Crowds Massachusetts to Follow NYC in Making Landlords Pay Broker Fees What Gothenburg Got Out of Congestion Pricing California Exempts Building Projects From Environmental Law The poaching of artificial intelligence researchers from the likes of OpenAI — with salaries in the tens of millions of dollars — and the debut of Meta's new Superintelligence group comes after the Facebook operator developed a reputation for 'having a dysfunctional team,' Toner said in an interview with Bloomberg TV. The practice of luring away high performers from each other's AI labs has intensified among Silicon Valley companies since the launch of ChatGPT, she said. 'The question is, can it turn around Meta's fortunes and turn it into a real juggernaut?' Toner said. 'It'll be difficult, there's a lot of organizational politics at play.' Meta's troubles began compounding when China's AI upstart DeepSeek came out of nowhere this year and put forward credible competition to Meta's open source models. 'The fact that DeepSeek was outshining them was really not a good look for the company,' according to Toner. Chief Executive Officer Mark Zuckerberg is now plowing financial resources in, but whether he'll be able to change organizational dynamics and make progress fast enough to retain top engineers is an open question. 'Can Meta convince them that they are moving fast enough?' Toner said. Toner, an influential voice in artificial intelligence, came into the limelight first as a board member of OpenAI and then for her vote to oust Sam Altman from the CEO post in late 2023. The Melbourne-educated academic departed from the board following Altman's brief stepping down and restoration to the top job, and has since advanced her career in studying the AI race between the US and China. That race is now spilling across borders as the two superpowers vie for the business and collaboration of other countries, Toner said. US companies like OpenAI and Chinese players like Alibaba Group Holding Ltd., DeepSeek and Zhipu AI are making plays for international partnerships with governments and businesses. South Korea's Kakao Corp. is integrating ChatGPT and other AI services into the country's most used social media platform, while Alibaba is adding new data centers in Southeast Asia. China has a long history of working with other governments and is chipping away at the US tech monopoly globally, Toner said. 'It's certainly a strong showing they're making,' she said. China's models are widely available even if they are less technically sophisticated. They compete on the basis that they're 'cheaper, easier to use, and they help you adopt and customize.' Toner hasn't interacted with Altman since their clash in the November 2023 OpenAI boardroom battle. 'At some point, we'll wind up at the same event, the AI world is pretty small,' she said. 'I'm sure we'll both be happy to shake each other's hand.' SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too America's Top Consumer-Sentiment Economist Is Worried How to Steal a House China's Homegrown Jewelry Superstar Pistachios Are Everywhere Right Now, Not Just in Dubai Chocolate ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
AI job predictions become corporate America's newest competitive sport
In late May, Anthropic CEO Dario Amodei appeared to kick open the door on a sensitive topic, warning that half of entry-level jobs could vanish within five years because of AI and push U.S. unemployment up to 20%. But Amodei is far from alone in sharing aloud that he foresees a workforce bloodbath. A new WSJ story highlights how other CEOs are also issuing dire predictions about AI's job impact, turning employment doom into something of a competitive sport. Several of these predictions came before Amodei's comments. For example, at JPMorgan's annual investor day earlier in May, its consumer banking chief Marianne Lake projected AI would 'enable' a 10% workforce reduction. But they've been coming fast, and growing more stark, ever since. In a note last month, Amazon's Andy Jassy warned employees to expect a smaller workforce due to the 'once-in-a-lifetime' technological shift that's afoot. ThredUp's CEO said at a conference last month that AI will destroy 'way more jobs than the average person thinks.' Not to be outdone, Ford's Jim Farley delivered perhaps the most sweeping claim yet, saying last week that AI will 'literally replace half of all white-collar workers in the U.S.' It's a dramatic shift from executives' previous cautious public statements about job displacement, notes the Journal. Indeed, the outlet notes that while some tech leaders — including from powerful AI companies — have proposed that fears are overblown, the growing string of warnings suggests massive restructurings are coming, whether people are ready for them or not. Sign in to access your portfolio
Medscape
35 minutes ago
- Medscape
New Trials, New Targets: New Hope for Alzheimer's
After decades of frustration and failure, the landscape of drug development for Alzheimer's disease (AD) is starting to shift beyond anti-amyloids. Fueled by a growing pipeline of investigational agents, a broader range of therapeutic targets, and a record number of active clinical trials, a growing, but cautious, optimism is taking hold. The Alzheimer's Drug Development Pipeline 2025 reported there are currently 138 novel drugs under evaluation in 182 clinical trials — up 9% from 2024. Initiated by Jeffrey L. Cummings, MD, and colleagues in 2016, this year's annual report showed these clinical trials are being conducted at more than 4500 sites worldwide and included more than 50,000 participants. 'There's great reason for optimism. It's not just the increased amount of clinical trials, but the targeted therapies being studied,' said Cummings, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada, Nevada, in a statement. Howard Fillit, MD, cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation, agreed. 'What's going on is really quite remarkable. We have the first disease-modifying drugs on the market, which is amazing, and I think the portfolio of drugs in development has changed dramatically from even 5 years ago,' Fillit told Medscape Medical News . James Rowe, PhD, professor of cognitive neurology, University of Cambridge, Cambridge, England, was equally impressed by the latest report. 'What strikes me is not just the number of new drugs but their range of targets in which they work, giving us multiple shots on goal,' Rowe commented during a media briefing on the report. The Next Big Thing? Currently 12 phase 3 trials are expected to report results this year. In an interview with Medscape Medical News , Cummings noted that 'one of the most interesting and probably most influential of the readouts that will occur this year' involves two trials evoke and evoke+ of the GLP-1 receptor antagonist semaglutide in patients with mild cognitive impairment (MCI) or mild AD dementia. 'Semaglutide is a drug approved for diabetes and obesity, and it has epidemiologic and laboratory support for testing in Alzheimer's disease. And what's important is that this is an oral medication and it would just be fabulous if we had an oral alternative for treatment,' said Cummings. Phase 3 data on the combination of xanomeline plus trospium, a medication approved for schizophrenia in adults, which is being tested for psychosis in AD, is also highly anticipated, Cummings said. 'There are no approved treatments for psychosis in Alzheimer's disease, so this is going to be a particularly interesting readout,' he noted. Cummings also highlighted BIIB080, Biogen's investigational antisense oligonucleotide targeting tau, as another promising compound for early-stage AD. The therapy received Fast Track designation from the FDA in April. In early testing, BIIB080 reduced soluble tau protein in cerebrospinal fluid (CSF), decreased aggregated tau pathology in the brain and showed favorable trends in exploratory clinical outcomes. New data on BIIB080 is expected in 2026. Hopes are also high for trontinemab (Roche), a modified version of the anti-amyloid monoclonal antibody gantenerumab. The therapy uses brain shuttle technology to improve its ability to cross the blood-brain barrier. 'This so-called brain shuttle technology is exciting because they've found a way to get much more of the antibody across the brain barrier and into the brain and engage the target. And this technology could be used to get other drugs into the brain,' Cummings said. The Big Picture There are currently 48 trials assessing 31 drugs in phase 3; 86 trials assessing 75 drugs in phase 2; and 48 trials assessing 45 drugs in phase 1. Of the 182 trials, 16 are long-term extensions of agents in prior trials. Since the beginning of 2024, 56 new trials entered the pipeline across all phases, including 10 new phase 3 trials. A total of 12 therapeutic agents are expected to complete phase 3 trials and 29 are scheduled to complete phase 2 in 2025. Disease-targeted therapies (DTTs) continue to dominate the AD drug pipeline. Biological DTTs comprise 30% of the pipeline and small molecule DTTs account for 43%. Drugs targeting cognitive enhancement make up 14% of the pipeline and drugs aimed at ameliorating AD neuropsychiatric symptoms comprise 11%. Repurposed agents represent 33% of the pipeline agents. In addition, biomarkers are among the primary outcomes of 27% of active trials. Beyond Amyloid: New Targets Anti-amyloid agents, lecanemab and donanemab, became the first disease-targeting medications for AD and represented a 'huge leap forward in our understanding and ability to treat AD,' Sheona Scales, PhD, director of research, Alzheimer's Research UK, told reporters attending the press briefing. Scales noted that a key focus of ongoing anti-amyloid research is to find ways to increase brain exposure and reduce the side effects of these agents. Beyond anti-amyloids, the latest pipeline report showed not only numerical growth but also increased biological diversity among the agents under investigation. 'Research is revealing even more complexities around how Alzheimer's disease starts and progresses, and this goes beyond amyloid. The current therapeutic pipeline has more diverse targets than in previous years,' Scales said. Similar to 2024, this year only 18% of drugs in the pipeline target amyloid-related pathophysiology, whereas 11% target tau-related processes. 'Neuroinflammation, in particular, is a highly active area of therapeutic development,' Emma Mead, PhD, interim chief scientific officer, Oxford Drug Discovery Institute, told reporters. 'Neuroinflammation is the brain's response to injury, infection or disease, and research has suggested that in neurodegenerative conditions, microglia, the immune cells of the brain, become dysregulated and this contributes to the damage associated with Alzheimer's disease,' Mead explained. Thirty drugs (22%) in the pipeline target neurotransmitter receptors, 24 (17%) address neuroinflammation/immune processes and 6% address synaptic plasticity/neuroprotection. Combination Therapies and Prevention Given the complexity of AD, it's become clear that targeting a single pathway may not be sufficient for effective treatment. Combination therapy targeting multiple complementary pathologic mechanisms will be necessary to maximize therapeutic effects. The 2025 AD drug pipeline includes 20 trials of combination therapies, comprising 11% of all current trials. Ten of these trials target aspects of both inflammation and amyloid. For example, two trials are testing dasatinib, in combination with quercetin, as a senolytic therapy for dementia. Senescent cells accumulate with age and are believed to contribute to age-related diseases like dementia. Six trials are assessing combinations of dextromethorphan and a CYP2D6 inhibitor for reducing agitation associated with dementia. Four trials are assessing the combination of xanomeline plus trospium. 'Because Alzheimer's disease is so complex and different pathologies develop at different times across the disease course, it's likely that in the future, patients are going to be offered specific treatments that target distinct mechanistic pathways depending on their disease stage,' Mead said. Rowe said one of the most compelling findings in the latest pipeline reported as the notable increase in late-phase trials focused on prevention. These AD prevention trials aim to intervene before symptoms appear — targeting individuals at high risk due to genetics, biomarkers, or early pathological changes — to delay or even prevent clinical onset. 'The aspiration to prevent, not just treat, is starting to be seen in the figures and that's very exciting,' he told the briefing. Repurposing Current Medications? About a third of the agents currently under investigation are repurposed medications — drugs originally approved for other conditions — which may offer a faster path to patient access. They include the GLP-1 receptor agonists (RAs) used to treat diabetes and obesity. In addition to semaglutide, another GLP-1 RA, liraglutide, demonstrated a 50% reduction in brain atrophy and 18% slower cognitive decline in the phase 2b ELAD clinical trial of adults with mild to moderate AD. The diabetes medication metformin is also in phase 3 testing for AD with results expected in 2026. Antihypertensive medications — including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) — are also being studied for their potential neuroprotective effects. A randomized trial of the ARB candesartan showed positive neurocognitive effects independent of, and in addition to, their blood-pressure lowering effects. Further, a low dose formulation of the antiepileptic levetiracetam has also shown potential in the treatment of MCI and early AD by targeting hippocampal hyperactivity, a hallmark of AD. Research has also hinted that antibiotics, antivirals, some vaccines, and anti-inflammatory medications may protect against dementia, possibly by mitigating pathogen-induced neuroinflammation. Closer to a Cure? 'Trial innovation' is also evident in the 2025 AD drug development pipeline, the report's authors noted, with plasma biomarkers playing a greater role in AD diagnosis. Recent studies have suggested that plasma p-tau 217 measures are equivalent in diagnostic accuracy to CSF biomarkers of AD pathology. Several trials entering the pipeline this year are using plasma p-tau 217 to confirm AD diagnosis and serve as an eligibility criterion for clinical trial participation. In one trial, eligibility was based on Aβ 42/40 plus the ratio of p-tau 217/nonphosphorylated tau 217; a separate trial used 'blood biomarkers' or past CSF or PET evidence of Aβ abnormalities for eligibility. CSF levels of microtubule-binding region tau243 have been shown to correlate with insoluble tau detected by tau PET imaging and are being used as a primary outcome measure in an anti-tau antibody trial. 'The use of biomarkers to determine eligibility and as outcomes in clinical trials shows the increasingly important role that biomarkers play in AD drug development,' Cummings and colleagues wrote. Summing up, they said the 2025 AD drug pipeline report demonstrates 'robust' momentum toward identifying new therapies for the treatment of AD. 'Seeing the broad range of scientific research that's taking place, I am extremely hopeful that we are closer than ever to finding a cure for Alzheimer's,' Cummings said in the news release.
